Genesis Private Wealth LLC Purchases New Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Genesis Private Wealth LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 3,915 shares of the biopharmaceutical company's stock, valued at approximately $362,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. nVerses Capital LLC acquired a new position in shares of Gilead Sciences during the 3rd quarter worth approximately $25,000. Valued Wealth Advisors LLC raised its holdings in shares of Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 161 shares during the period. Decker Retirement Planning Inc. acquired a new position in shares of Gilead Sciences during the 4th quarter valued at about $29,000. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Gilead Sciences in the second quarter valued at about $33,000. Finally, Quarry LP purchased a new position in Gilead Sciences during the second quarter worth about $43,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Insiders Place Their Bets

In related news, insider Merdad Parsey sold 25,590 shares of the business's stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the sale, the insider now directly owns 99,599 shares in the company, valued at approximately $9,113,308.50. The trade was a 20.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 248,645 shares of the stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the transaction, the chief financial officer now directly owns 138,919 shares in the company, valued at approximately $12,886,126.44. This represents a 64.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 456,234 shares of company stock valued at $42,130,461 in the last quarter. 0.29% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on GILD shares. Daiwa America raised Gilead Sciences to a "hold" rating in a research report on Monday, November 18th. Bank of America restated a "buy" rating and issued a $109.00 price objective on shares of Gilead Sciences in a report on Tuesday, December 10th. Leerink Partnrs raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Monday, October 21st. Truist Financial raised their price target on shares of Gilead Sciences from $83.00 to $97.00 and gave the company a "hold" rating in a research report on Friday, November 8th. Finally, The Goldman Sachs Group boosted their target price on shares of Gilead Sciences from $74.00 to $84.00 and gave the stock a "neutral" rating in a research note on Thursday, November 7th. Eleven investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences currently has a consensus rating of "Moderate Buy" and an average price target of $97.96.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $92.96 on Wednesday. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The company's 50-day moving average price is $91.65 and its 200 day moving average price is $84.38. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.90. The stock has a market cap of $115.85 billion, a price-to-earnings ratio of 1,032.89, a PEG ratio of 1.29 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter last year, the business posted $2.29 earnings per share. Gilead Sciences's revenue was up 7.0% compared to the same quarter last year. As a group, research analysts forecast that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were issued a $0.77 dividend. The ex-dividend date of this dividend was Friday, December 13th. This represents a $3.08 annualized dividend and a yield of 3.31%. Gilead Sciences's dividend payout ratio (DPR) is presently 3,422.22%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.